Abstract
Recurrence of infection is a challenge in treatment of Clostridioides difficile infection (CDI), observed in 25% of patients. The first-line antibiotics disturb the gut microbiota, exacerbating the already disrupted commensal gut homeostasis and allow for C. difficile colonization. Narrow-spectrum antibiotics are critical for selective targeting of C. difficile while preserving beneficial gut flora, thereby mitigating recurrence. Our study investigates a novel class of highly selective, nitroimidazole-based oxadiazole antibacterials. We detail the chemical basis for their exceptional selectivity against C. difficile over commensal bacteria and elucidate their mechanism of action. Oxadiazole 2 inhibits penicillin-binding proteins 1 and 3 involved in septal peptidoglycan biosynthesis during vegetative cell division. We further demonstrate by whole-genome sequencing that treatment of mice with oxadiazole 2 does not disrupt the gut microflora and confers an impediment to colonization by C. difficile. This work is foundational for development of a new generation of narrow-spectrum therapeutics to combat CDI.
Funding Information
  • Eck Institute for Global Health, University of Notre Dame
  • American Heart Association (25PRE1375230)
  • National Institute of Allergy and Infectious Diseases (AI198244)
  • National Institute of General Medical Sciences (T32 GM075762)
  • National Institute of General Medical Sciences (T32 GM145773)

This publication has 44 references indexed in Scilit: